The sustainability of weight-loss drugs is under scrutiny as new research shows that people who stop taking glucagon-like peptide-1 (GLP-1) agonists regain the pounds at a steady rate, returning to ...

A class of medications best known for treating diabetes and obesity may also reduce the risk of addiction—and help people who already have one, a new study shows.

New research suggests the weight-loss medications could be powerful tools in tackling substance use disorders.

A popular class of drugs for treating diabetes and obesity may reduce addiction, including abuse of alcohol, tobacco, cannabis, opioids and cocaine, according to research published March 4 by ...

The blockbuster GLP-1 drugs that have reshaped the treatment of diabetes and obesity may help prevent multiple substance use disorders — and reduce the tragic outcomes they cause, a large new study ...

To learn more about our editorial approach, explore The Direct Message methodology. A class of drugs that millions of people take to manage diabetes and lose weight appears to cut substance use deaths ...

The list of health conditions that benefit from the GLP-1 weight loss and diabetes drugs like Ozempic, Wegovy, Mounjaro and Zepbound, continues to grow. The drugs are already approved to lower the ...

GLP-1 weight loss drugs have quickly moved from medical journals to household conversations, reshaping how Americans think about obesity, diabetes and weight loss. Headlines often describe them as ...